CAR-T has a lot of promise, but some big challenges remain, experts at BIO, ASCO say
Many issues around CAR-T remain to be hashed out, but many experts pointed to infrastructure and clinics' capabilities as crucial.
Experts at BIO, ASCO weigh in on CAR-Ts versus bispecific antibodies
CAR-Ts have generated excitement, but bispecific monoclonal antibodies may continue to have a competitive edge in some cases.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
bluebird shares recover after slump following ASCO CAR-T data presentation
Progression-free survival rates from bb2121 in multiple myeloma still impress despite investor reaction.
Session at ASCO shows community oncology success in precision medicine
Experts went into the nitty-gritty aspects of how the community oncology setting can implement precision medicine trials.
Updated ASCO data from Loxo study show more patients responding
Interim data from the Phase I data show 77 percent overall response rate, including 74 percent confirmed responses.